Major clinical endpoints of allogeneic HSCT by study group
. | . | HLA class I disparity n = 137 . | . | . | |
|---|---|---|---|---|---|
. | HLA class I and II identity, n = 237 . | KIR ligand-compatible n = 89 . | KIR ligand-incompatible n = 48 . | P . | |
| Leukemic relapse, no. events/no. patients (%) | |||||
| Early disease stages | 23/162 (14) | 4/47 (9) | 0/22 (0) | < .04* | |
| Advanced disease stages | 16/75 (21) | 6/42 (14) | 2/26 (8) | NS* | |
| Total | 39/237 (16) | 10/89 (11) | 2/48 (4) | < .04* | |
| 5-year leukemic relapse estimate, % ± SE | |||||
| Early disease stages | 17 ± 3 | 13 ± 6 | 0 | NS | |
| Advanced disease stages | 40 ± 10 | 27 ± 10 | 11 ± 7 | NS | |
| Total | 22 ± 3 | 18 ± 6 | 5 ± 3 | < .05 | |
| Primary graft failure, no. events (%) | 1 (0.4) | 2 (2.3) | 3 (6.3) | < .02 | |
| 30-day primary graft failure estimate, % ± SE | 0.4 ± 0.4 | 2.5 ± 1.7 | 6.4 ± 3.6 | < .02 | |
| Transplantation-related mortality, no. events/no. patients (%) | |||||
| Early disease stages | 32/162 (20) | 11/47 (23) | 5/22 (23) | NS | |
| Advanced disease stages | 33/75 (44) | 19/42 (45) | 12/26 (46) | NS | |
| Total | 65/237 (27) | 30/89 (34) | 17/48 (35) | NS | |
| 5-year estimate of transplantation-related mortality, % ± SE | |||||
| Early disease stages | 22 ± 3 | 24 ± 6 | 27 ± 10 | NS | |
| Advanced disease stages | 46 ± 6 | 49 ± 8 | 48 ± 10 | NS | |
| Total | 32 ± 3 | 38 ± 7 | 39 ± 7 | NS | |
| Survival, no. survivors/no. patients (%) | |||||
| Early disease stages | 114/162 (70) | 34/47 (72) | 17/22 (77) | NS | |
| Advanced disease stages | 29/75 (39) | 17/42 (40) | 12/26 (46) | NS | |
| Total | 143/237 (60) | 51/89 (57) | 29/48 (60) | NS | |
| 5-year survival estimate, % ± SE | |||||
| Early disease stages | 66 ± 5 | 72 ± 7 | 73 ± 10 | NS | |
| Advanced disease stages | 30 ± 7 | 33 ± 11 | 46 ± 10 | NS | |
| Total | 55 ± 4 | 53 ± 6 | 58 ± 7 | NS | |
| Event-free survival, no. event-free survivors/no. patients (%) | |||||
| Early disease stages | 107/162 (66) | 32/47 (68) | 17/22 (77) | NS | |
| Advanced disease stages | 26/75 (35) | 17/42 (40) | 12/26 (46) | NS | |
| Total | 133/237 (56) | 49/89 (55) | 29/48 (60) | NS | |
| 5-year event-free survival estimate, % ± SE | |||||
| Early disease stages | 63 ± 4 | 66 ± 7 | 73 ± 10 | NS | |
| Advanced disease stages | 30 ± 7 | 33 ± 11 | 46 ± 10 | NS | |
| Total | 53 ± 4 | 50 ± 6 | 58 ± 7 | NS | |
. | . | HLA class I disparity n = 137 . | . | . | |
|---|---|---|---|---|---|
. | HLA class I and II identity, n = 237 . | KIR ligand-compatible n = 89 . | KIR ligand-incompatible n = 48 . | P . | |
| Leukemic relapse, no. events/no. patients (%) | |||||
| Early disease stages | 23/162 (14) | 4/47 (9) | 0/22 (0) | < .04* | |
| Advanced disease stages | 16/75 (21) | 6/42 (14) | 2/26 (8) | NS* | |
| Total | 39/237 (16) | 10/89 (11) | 2/48 (4) | < .04* | |
| 5-year leukemic relapse estimate, % ± SE | |||||
| Early disease stages | 17 ± 3 | 13 ± 6 | 0 | NS | |
| Advanced disease stages | 40 ± 10 | 27 ± 10 | 11 ± 7 | NS | |
| Total | 22 ± 3 | 18 ± 6 | 5 ± 3 | < .05 | |
| Primary graft failure, no. events (%) | 1 (0.4) | 2 (2.3) | 3 (6.3) | < .02 | |
| 30-day primary graft failure estimate, % ± SE | 0.4 ± 0.4 | 2.5 ± 1.7 | 6.4 ± 3.6 | < .02 | |
| Transplantation-related mortality, no. events/no. patients (%) | |||||
| Early disease stages | 32/162 (20) | 11/47 (23) | 5/22 (23) | NS | |
| Advanced disease stages | 33/75 (44) | 19/42 (45) | 12/26 (46) | NS | |
| Total | 65/237 (27) | 30/89 (34) | 17/48 (35) | NS | |
| 5-year estimate of transplantation-related mortality, % ± SE | |||||
| Early disease stages | 22 ± 3 | 24 ± 6 | 27 ± 10 | NS | |
| Advanced disease stages | 46 ± 6 | 49 ± 8 | 48 ± 10 | NS | |
| Total | 32 ± 3 | 38 ± 7 | 39 ± 7 | NS | |
| Survival, no. survivors/no. patients (%) | |||||
| Early disease stages | 114/162 (70) | 34/47 (72) | 17/22 (77) | NS | |
| Advanced disease stages | 29/75 (39) | 17/42 (40) | 12/26 (46) | NS | |
| Total | 143/237 (60) | 51/89 (57) | 29/48 (60) | NS | |
| 5-year survival estimate, % ± SE | |||||
| Early disease stages | 66 ± 5 | 72 ± 7 | 73 ± 10 | NS | |
| Advanced disease stages | 30 ± 7 | 33 ± 11 | 46 ± 10 | NS | |
| Total | 55 ± 4 | 53 ± 6 | 58 ± 7 | NS | |
| Event-free survival, no. event-free survivors/no. patients (%) | |||||
| Early disease stages | 107/162 (66) | 32/47 (68) | 17/22 (77) | NS | |
| Advanced disease stages | 26/75 (35) | 17/42 (40) | 12/26 (46) | NS | |
| Total | 133/237 (56) | 49/89 (55) | 29/48 (60) | NS | |
| 5-year event-free survival estimate, % ± SE | |||||
| Early disease stages | 63 ± 4 | 66 ± 7 | 73 ± 10 | NS | |
| Advanced disease stages | 30 ± 7 | 33 ± 11 | 46 ± 10 | NS | |
| Total | 53 ± 4 | 50 ± 6 | 58 ± 7 | NS | |
NS indicates nonsignificant.
Likelihood ratio chi-square statistics